REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy.
Comments and feedback are welcomed. If you would like to leave a comment, please fill out the form below. You can also subscribe to comments for this article via RSS.
Name (required)
Email (required, will not be published)
Web site (optional)
The Myeloma Beacon is brought to you in part by:
Leave a comment